Lymphadenectomy improves outcome in dogs with resected Kiupel high-grade cutaneous mast cell tumours and overtly metastatic regional lymph nodes.
Journal
The Journal of small animal practice
ISSN: 1748-5827
Titre abrégé: J Small Anim Pract
Pays: England
ID NLM: 0165053
Informations de publication
Date de publication:
09 2022
09 2022
Historique:
revised:
12
04
2022
received:
31
01
2022
accepted:
09
05
2022
pubmed:
23
6
2022
medline:
15
9
2022
entrez:
22
6
2022
Statut:
ppublish
Résumé
Historically, the prognosis for dogs with stage II Kiupel high-grade cutaneous mast cell tumours has been considered poor. The aim of this study was to explore the impact of lymphadenectomy on outcome in dogs with Kiupel high-grade cutaneous mast cell tumours and overt regional lymph node metastasis. Data from dogs with completely staged Kiupel high-grade cutaneous mast cell tumours with overt and/or certain regional lymph node metastasis undergoing excision of the primary tumours and adjuvant medical treatment were extracted. Dogs with a cytological diagnosis of regional lymph node metastasis that did not undergo lymphadenectomy were compared with dogs that underwent lymphadenectomy and had a histological diagnosis of overt lymph node metastasis. Forty-nine dogs were included, 18 did not undergo lymphadenectomy while 31 underwent lymphadenectomy. Median time to progression was significantly shorter in dogs that did not undergo lymphadenectomy (150 days, 95% confidence interval: 129 to 170) compared to the other dogs (229 days, 95% confidence interval: 191 to 266). Median survival time was also shorter in dogs that did not undergo lymphadenectomy (250 days, 95% confidence interval: 191 to 308) compared to dogs that underwent lymphadenectomy (371 days, 95% confidence interval: 311 to 430). On multivariable analysis, lack of lymphadenectomy was associated with higher risk of overall tumour progression (hazard ratio: 2.05, 95% confidence interval: 1.02 to 4.13), nodal progression (hazard ratio: 3.4, 95% confidence interval: 1.65 to 7.02) and tumour-related death (hazard ratio 3.63, 95% confidence interval: 1.72 to 7.66), whereas tumour size was associated with higher risk of local recurrence (hazard ratio: 3.61, 95% confidence interval: 1.06 to 13). Regional lymphadenectomy may improve outcome in dogs with biologically aggressive cutaneous mast cell tumours.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
661-669Informations de copyright
© 2022 British Small Animal Veterinary Association.
Références
Baginski, H., Davis, G. & Bastian, R. P. (2014) The prognostic value of lymph node metastasis with grade 2 MCTs in dogs: 55 cases (2001-2010). Journal of the American Animal Hospital Association 50, 89-95
Blackwood, L., Murphy, S., Buracco, P., et al. (2012) European consensus document on mast cell tumours in dogs and cats. Veterinary and Comparative Oncology 10, 1-29
Dobson, M. J. & Scase, J. T. (2007) Advance in the diagnosis and management of cutaneous mast cell tumours in dogs. The Journal of Small Animal Practice 48, 424-431
Donnelly, L., Mulin, C., Balko, J., et al. (2015) Evaluation of histological grade and histologically tumor-free margins as predictors of local recurrence in completely excised canine mast cell tumors. Veterinary and Comparative Oncology 13, 70-76
Dores, B. C., Milovancev, M. & Russel, S. D. (2017) Comparison of histologic margin status in low-grade cutaneous and subcutaneous mast cell tumours examined by radial and tangential sections. Veterinary and Comparative Oncology 16, 125-130
Halsted, S. W. (1907) The results of radical operations for the cure of carcinoma of the breast. Annals of Surgery 46, 1-19
Hayes, A., Adams, V., Smith, K., et al. (2007) Vinblastine and prednisolone chemotherapy for surgically excised grade III canine cutaneous mast cell tumors. Veterinary and Comparative Oncology 5, 168-176
Horta, S. R., Lavalle, E. G., Montiero, L., et al. (2018) Assessment of canine mast cell tumor mortality risk based on clinical, histological and molecular features. Veterinary Pathology 55, 212-223
Hume, T. C., Kiupel, M., Rigatti, L., et al. (2011) Outcomes of dogs with grade 3 mast cell tumors: 43 cases (1997-2007). Journal of the American Animal Hospital Association 47, 37-44
Kawada, K. & Taketo, M. M. (2011) Significant and mechanism of lymph node metastasis in cancer progression. Cancer Research 71, 1214-1218
Kiupel, M., Webster, J. D., Bailey, K. L., et al. (2011) Proposal of a 2-tier histologic grading system for canine cutaneous mast cell tumors to more accurately predict biological behaviour. Veterinary Pathology 48, 147-155
Krick, E. L., Billings, A. P., Shofer, S. F., et al. (2009) Cytological lymph node evaluation in dogs with mast cell tumors: association with grade and survival. Veterinary and Comparative Oncology 27, 130-138
Lejeune, A., Skorupski, K., Frazier, S., et al. (2015) Aggressive locale therapy combined with systemic chemotherapy provides long-term control in grade II stage 2 canine mast cell tumor: 21 cases (1999-2012). Veterinary and Comparative Oncology 13, 267-280
Liptac, M. J. (2020) Histologic margins and residual tumour classification scheme: is it time to use a validated scheme in human oncology to standardise margin assessment in veterinary oncology? Veterinary and Comparative Oncology 18, 25-35
Marconato, L., Polton, G., Stefanello, D., et al. (2018) Therapeutic impact of regional lymphadenectomy in canine stage II cutaneous mast cell tumors. Veterinary and Comparative Oncology 16, 680-589
Marconato, L., Stefanello, D., Kiupel, M., et al. (2020) Adjuvant medical therapy provides no therapeutic benefit in the treatment of dogs with low-grade mast cell tumors and early nodal metastasis undergoing surgery. Veterinary and Comparative Oncology 18, 409-415
Mendez, S. E., Drobatz, K. J., Duda, L., et al. (2020) Treating the locoregional lymph node with radiation and/or surgery significantly improves outcome in dogs with high-grade mast cell tumors. Veterinary and Comparative Oncology 18, 239-246
Miller, L. R., Lelyveld, V. S., Warland, J., et al. (2016) A retrospective review of treatment and response of high-risk mast cell tumors in dogs. Veterinary and Comparative Oncology 14, 361-370
Nguyen, S. M., Thamm, D. H., Valli, D. M., et al. (2015) Response evaluation criteria for solid tumours in dogs (v1.0): a Veterinary Cooperative Oncology Group (VCOG) consensus documents. Veterinary and Comparative Oncology 13, 176-183
Owen, L. N. (1980) TNM Classification of Tumors in Domestic Animals. 1st edn. World Health Organization, Geneva, Switzerland
Patnaik, A. K., Ehler, W. J. & MacEwen, E. G. (1984) Canine cutaneous mast cell tumor: morphologic grading and survival time in 83 dogs. Veterinary Pathology 21, 469-474
Pizzoni, S., Sabattini, S., Stefanello, D., et al. (2018) Features and prognostic impact of distant metastases in 45 dogs with de novo stage IV cutaneous mast cell tumours: a prospective study. Veterinary and Comparative Oncology 16, 28-36
Stefanello, D., Buracco, P., Sabbatini, S., et al. (2015) Comparison of 2- and 3-category histologic grading systems for predicting the presence of metastasis at the time of initial evaluation in dogs with cutaneous mast cell tumors: 386 cases (2009-2014). Journal of the American Veterinary Medical Association 246, 765-769
Suami, H., Yamashita, S. & Miranda-Soto, M. A. (2013) Lymphatic territories (lymphosomes) in a canine: an animal model for investigation of postoperative lymphatic alterations. PLoS One 8, e69222. https://doi.org/10.1371/journal.pone.0069222
Warland, J., Fuster-Amores, I., Newbury, W., et al. (2014) The utility of staging in canine mast cell tumors. Veterinary and Comparative Oncology 12, 287-298
Weishaar, K. M., Thamm, D. H., Worley, D. R., et al. (2014) Correlation of nodal mast cells with clinical outcome in dogs with mast cell tumor and a proposed classification system for the evaluation of node metastasis. Journal of Comparative Pathology 151, 329-338
Wong, S. Y. & Hynes, R. O. (2006) Lymphatic or hematogenous dissemination: how does a metastatic tumor cell decide? Cell Cycle 5, 812-817